Nkarta (NKTX) Projected to Announce Quarterly Earnings on Tuesday

Key Points

• Nkarta is expected to report Q3 2026 earnings on November 10, with analysts projecting a loss of $0.40 per share. The company previously reported a $0.54-per-share loss, missing consensus by $0.18.
• NKTX shares recently traded at $1.56, near their 52-week low of $1.48 and well below the 50-day and 200-day moving averages. The company has a market capitalization of approximately $112 million.
• Analyst sentiment remains mixed but leans positive, with a consensus rating of “Moderate Buy” and an average price target of $11.20; ratings include one Strong Buy, five Buys and one Sell.

Nkarta (NASDAQ:NKTX - Get Free Report) is expected to be releasing its Q3 2026 resultson Tuesday, November 10th. Analysts expect Nkarta to announce earnings of ($0.40) per share for the quarter. Parties can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.18). On average, analysts expect Nkarta to post ($1.60) EPS for the current fiscal year and ($1.46) EPS for the next fiscal year.

Nkarta Price Performance

Shares of NKTX stock traded up $0.04 during trading hours on Tuesday, reaching $1.56. 231,659 shares of the company were exchanged, compared to its average volume of 759,912. Nkarta has a fifty-two week low of $1.48 and a fifty-two week high of $3.72. The stock's fifty day moving average is $2.42 and its two-hundred day moving average is $2.52. The company has a market cap of $112.09 million, a price-to-earnings ratio of -1.00 and a beta of 0.93.

Analysts Set New Price Targets

Several research analysts have issued reports on NKTX shares. Stifel Nicolaus reduced their price objective on Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, August 14th. HC Wainwright started coverage on Nkarta in a research note on Monday. They issued a "buy" rating for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Nkarta in a research report on Monday, September 21st. Finally, Wall Street Zen downgraded Nkarta from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $11.20.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. The company's platform is designed to produce allogeneic, or donor-derived, NK cells that can be engineered with chimeric antigen receptors (CARs) to recognize and attack targeted cells.

Nkarta's research and development programs have included NKX019, a CD19-targeted CAR NK-cell therapy investigated for B-cell malignancies and autoimmune disorders, and NKX101, an NKG2D-targeted CAR NK-cell therapy developed for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.